All News

In the aftermath of the Dobbs v Jackson Women’s Health Organization ruling, Anita Allen, PhD, highlights the challenges to abortion rights in the United States, emphasizing disparities faced by marginalized communities, outlining threats to reproductive health care, and calling for collective action and advocacy to defend constitutional privacy and uphold the dignity of all individuals.

Two posters presented at the American Society for Reproductive Medicine 2023 Scientific Congress & Expo address racial and socioeconomic factors that impact fertility and birth outcomes.

At AMCP Nexus, Evernorth's Aimee Tharaldson, PharmD, provided an overview of which medications the FDA has approved in 2023 and what’s to come in nononcology areas over the next 5 years, including new drugs for Alzheimer disease, hemophilia, and nonalcoholic steatohepatitis (NASH).

A new analysis has determined potential risk factors for developing myasthenia gravis following COVID-19 vaccination, with symptoms likely to appear within 2 weeks of receipt of a COVID-19 vaccine.

During ESMO Congress 2023, sessions will focus on hot topics in therapeutic areas, such as the use of immunotherapies in both the neoadjuvant and adjuvant settings, as well as nontherapeutic topics, such as the needs of caregivers and advances in technology.

Amazon Prime air service is testing delivery of medication within an hour or ordering; Surging insurance costs are affecting 150 million Americans; Opponents of President Joe Biden's mental health care proposal argue potential rules could hinder access to quality care.

Experts in colorectal cancer (CRC) discussed the new health recommendations from the Network for Excellence in Health Innovations report and how they apply to the disparities in screening for CRC.

Panelists at AMCP Nexus provided an overview of the US obesity epidemic, dispelling myths about the causes of obesity, highlighting racial and economic disparities across the nation, and tackling how the managed care space can ensure accessibility to care for all patients.

"The racial and ethnic distribution of United States sperm donors differs significantly from the United States population, particularly for those of African American or Black descent,” Cassie Hobbs, MD, explained.

The results for a proposed aflibercept (Eylea) biosimilar and an accepted ranibizumab (Lucentis) biosimilar were presented at Euretina Congress 2023.

This group of cancers remains a challenge to diagnose, can be rapidly progressive, and requires complex treatment and follow-up care, research suggests.

Two posters presented at the American Society for Reproductive Medicine (ASRM) 2023 Scientific Congress & Expo showed trends in funding and insurance coverage for individuals seeking fertility care.

A session at AMCP Nexus on the use of artificial intelligence (AI) and machine learning (ML) in managed care highlights some real-world examples of successful implementation of these technologies.

Young women with sickle cell disease have a higher prevalence of heavy menstrual bleeding and dysmenorrhea.

Wiyatta Fahnbulleh, PsyD, and Pamela Blackwell, PsyD, LMSW, presented on the cultural limitations of the Personality Assessment Inventory and Minnesota Multiphasic Personality Inventory for assessing individuals for third-party reproduction.

A 2022 yearlong initiative at Summa Health Cancer Institute saw 100% of its patients with head and neck cancer undergoing radiation treatment referred to an oncology dietician for nutritional support and/or speech and swallow therapy.

The anti–PD-1 agent pembrolizumab was granted a new indication to treat patients with resectable non–small cell lung cancer (NSCLC) as a neoadjuvant treatment with chemotherapy and continued as adjuvant treatment after surgery.

Nearly 50% of pregnancies worldwide are unplanned, leading to significant health, economic, and environmental consequences, Stephanie Page, MD, PhD, explains in her presentation at the American Society for Reproductive Medicine 2023 Scientific Congress & Expo.

School nurses play an overworked and understaffed role; Merck's immunotherapy Keytruda (pembroilzumab) has been granted approval for pre- and postsurgical treatment in lung cancer; the FDA is helping to curb tobacco-related health disparities.

The marketing denial orders were due to what the FDA stated as insufficient data supporting the products' additional benefit for adults switching from smoking cigarettes to vaping or cessation.

People who inject drugs tended to have quicker COVID-19 vaccination uptake if they had HIV infection and viral suppression.

The data presents compelling evidence for the sustained efficacy and safety of the oral JAK1 inhibitor in the treatment of moderate to severe atopic dermatitis over an extended 140-week period.

Age played a part in the decrease in vision testing in adolescents, along with fewer reported tests in primary and school-based settings.

The 2023 Fall Clinical Dermatology conference will take place in Las Vegas and be livestreamed from October 19 to 22; topics of interest to be covered include atopic dermatitis (AD), Janus kinase (JAK) inhibitors, and psoriasis.

The level of biosimilar market sustainability differs between countries, largely due to variances in biosimilar policies and years of experience managing a biosimilar market.

Medicare Advantage star ratings reveal shifts in plan quality and performance; Rite Aid seeks debt reduction and restructures amid financial challenges; workers secure improved wages and staffing

Investigators evaluated 70 patients in a retrospective study.

Crinetics announced findings from the PATHFNDR-1 trial showing the investigative oral daily drug may provide patients with the rare disease an alternative from recurring injection therapy.

Pembrolizumab plus chemotherapy prior to surgery, followed by resection and single-agent pembrolizumab in the adjuvant setting, significantly improved overall survival (OS) vs neoadjuvant placebo plus chemotherapy followed by adjuvant placebo in patients with resectable stage II, IIIA, or IIIB (T3-4N2) non–small cell lung cancer, meeting the dual primary end point of the phase 3 KEYNOTE-671 trial.

Results show engaging in unstructured physical activities, even those of low intensity and carried out in the morning and early afternoon, is linked to reduced average glucose levels throughout the day and night.